---
title: "Liquidia Corporation (NASDAQ:LQDA) Q4 2025 earnings call transcript"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278265526.md"
description: "Liquidia Corporation (NASDAQ:LQDA) reported its Q4 2025 earnings, surpassing expectations with an EPS of $0.15 compared to the anticipated $0.08. The earnings call took place on March 5, 2026, where the company provided a financial update and discussed its performance for the full year 2025."
datetime: "2026-03-08T12:23:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278265526.md)
  - [en](https://longbridge.com/en/news/278265526.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278265526.md)
---

# Liquidia Corporation (NASDAQ:LQDA) Q4 2025 earnings call transcript

Liquidia Corporation (NASDAQ:LQDA) Q4 2025 Earnings Call Transcript March 5, 2026 Liquidia Corporation beats earnings expectations. Reported EPS is $0.15, expectations were $0.08. Operator: Good morning, and welcome to the Liquidia Corporation Full Year 2025 Financial Results and Corporate Update Conference Call. My name is Josh, and I will be your operator today. A question \[…\]

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Gossamer Bio Receives Nasdaq Minimum Bid Price Deficiency Notice](https://longbridge.com/en/news/282247265.md)
- [Liquidia CEO Roger Jeffs disposes of USD 1.3 million common shares](https://longbridge.com/en/news/282745700.md)
- [Liquidia Insider Sold Shares Worth $280,139, According to a Recent SEC Filing](https://longbridge.com/en/news/282747545.md)
- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)
- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)